Circulating tumour DNA (ctDNA) as a predictor of progression-free and overall survival in non-resectable pancreatic cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

This systematic review and meta-analysis synthesised current evidence on circulating tumour DNA (ctDNA) for predicting clinical outcomes in patients with non-resectable pancreatic ductal adenocarcinoma (PDAC).

Methods

PubMed, Embase, and Cochrane databases were searched up to 31/01/2025. Eligible studies reported prognostic value of ctDNA in patients with non-resectable PDAC. Meta-analyses evaluated associations between baseline ctDNA and changes in ctDNA during treatment (ctDNA kinetics) and survival outcomes. Risk of bias was assessed using the Quality in Prognosis Studies (QUIPS) tool.

Results

Sixty-four studies involving 5652 patients with non-resectable PDAC were included, with 24 studies contributing to meta-analyses. High baseline ctDNA level implied

SUBMITTER: Steiniche MM 

PROVIDER: S-EPMC12799495 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature